Jiangsu Hengrui Medicine (SHA:600276, HKG:1276) obtained the approval of China's drug regulator to start clinical trials on HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors.
The other drugs include SHR-9839, adebrelimab injection, bevacizumab injection and SHR-A2102 for injection, according to a filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments